Chamber-specific human iPSC-derived cardiomyocytes for disease modeling and safety

iPSC-derived cardiomyocytes for drug discovery, research and cardiotoxicity studies

Terminally differentiated cardiomyocytes derived from human iPSCs recapitulate key features of healthy human cardiac biology and function, providing a robust in vitro system for drug discovery, toxicity assessment, and fundamental research into cardiac health and disease. Axol offers highly validated, chamber-specific cardiomyocytes that exhibit distinct atrial or ventricular pharmacology and phenotypes, generated from both female and male donors.

To further enhance the predictive power of iPSC-derived cardiomyocyte platforms, we continue to innovate and optimize our technologies. For applications requiring increased cellular maturity, we have developed MyoMax, a proprietary maturation medium that specifically promotes advanced functional and structural maturation of ventricular iPSC-derived cardiomyocytes.

Comprehensive user guides and complete media kits streamline the establishment and scale up of iPSC-based cardiac models, and our scientific team are always available to help.